105 HIGH RESPONSE RATE FOR AZACITIDINE-LENALIDOMIDE (VI-LEN) COMBINATION IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - VILEN-01 PROTOCOL UPDATE. (April 2015) - Mittelman, M.